David Miller
Co-founder / CSO
Melio Bio
Melio Bio applies insights derived from human genetics to advance cardiometabolic health. The company focuses on translating genetic data into actionable strategies for improving metabolic outcomes. This approach aims to create more effective pathways for managing cardiovascular and metabolic conditions.
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Zoë Johnson
Executive Chair / Co-founder
Product
Problem
Current approaches to cardiometabolic disease treatment often lack specificity, leading to suboptimal patient outcomes and limited efficacy. The underlying genetic drivers of these complex conditions are not fully leveraged to inform therapeutic development.
Solution
Melio Bio is a biotechnology company focused on translating human genetic insights into novel therapeutic strategies for cardiometabolic diseases. By identifying and validating genetic targets, the company aims to develop precision medicines that address the root causes of conditions such as diabetes, obesity, and cardiovascular disorders. This approach facilitates the creation of more effective and personalized treatment options, ultimately improving patient health trajectories.
Target Audience
The primary target audience includes pharmaceutical companies and academic research institutions engaged in drug discovery and development for cardiometabolic diseases.
Features
- Identification of novel therapeutic targets through human genetic data analysis.
- Development of precision medicines tailored to specific genetic profiles.
- Focus on cardiometabolic diseases including diabetes, obesity, and cardiovascular disorders.
- Translation of genetic discoveries into actionable drug development pathways.